Formulation Development
Amarna Therapeutics Partners With NorthX Biologics to Advance Gene Therapy Development
Amarna Therapeutics recently announced its strategic collaboration with NorthX Biologics, a leading biologics manufacturing partner. This partnership represents a major step in advancing the clinical…
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals
Medigene AG recently announced a $1 million milestone payment from Regeneron Pharmaceuticals, Inc. was triggered. Regeneron purchased the MAGE-A4-TCR program as part of its acquisition…
Roivant Announces Topline Results From Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Kinevant Sciences recently announced its Phase 2 study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. The Phase 2 RESOLVE-Lung study…
Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 Million to Intas Pharmaceuticals Ltd.
Coherus BioSciences, Inc. recently announced it has entered into an asset purchase agreement (the Agreement) dated December 2, 2024, with Intas Pharmaceuticals Ltd. (Intas) for…
Palisade Bio Announces Preliminary Data From Phase 1 Clinical Study for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe & Well Tolerated
Palisade Bio, Inc recently announced preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human clinical study for…
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 Clinical Trial
Kairos Pharma Ltd. recently announced the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for…
Recursion Announces First Patient Dosed in Phase 1/2 Clinical Study of a Potential First-in-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors & Lymphoma
Recursion recently announced the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of…
Lonza Launches Tailored Offering for Smart Capsules Companies Developing Oral Delivery Solutions for Biologic Drugs
Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, recently announced an expansion of its service offering for orally delivered biologic therapies…
Veranova Recognized as One of SOCMA’s 25 Companies for Industry-Leading Safety Programs
Veranova recently announced it has been recognized by The Society of Chemical Manufacturers & Affiliates, Inc. (SOCMA) as a recipient of its prestigious 2024 Safety…
Olema Oncology Announces New Clinical Trial Collaboration & Supply Agreement
Olema Pharmaceuticals, Inc. recently announced a new clinical trial collaboration and supply agreement with Novartis in frontline metastatic breast cancer. Olema has also entered into…
PTC Therapeutics Enters Global License & Collaboration Agreement With Novartis
PTC Therapeutics, Inc. recently announced the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:…
Ocular Therapeutix Announces More Than 300 Subjects Randomized in SOL-1
Ocular Therapeutix, Inc. recently announced more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI (axitinib intravitreal implant, also known…
NovelMed Receives FDA IND Approval for the First Anti-Bb Alternative Pathway Blocker for Treating Primary Immunoglobulin A Nephropathy (IgAN): A Renal Disorder
NovelMed recently announced the US FDA has granted clearance for Ruxoprubart, an investigational drug, to commence an efficacy trial for the treatment of Immunoglobulin A…
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals, Inc. recently announced the US FDA has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk…
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
Sana Biotechnology, Inc. recently announced the US FDA granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus (SLE), which includes extrarenal lupus and…
Lin BioScience Receives FDA Fast Track Designation For LBS-007
Lin BioScience recently announced its lead pipeline, LBS-007, has been granted Fast Track Designation by the US FDA for the treatment of acute myeloid leukemia.…
Marinomed Biotech AG Signs Agreement for Sale of Carragelose Business to Unither Pharmaceuticals
Marinomed Biotech AG has signed an agreement on the sale of its Carragelose business to the French CDMO Unither Pharmaceuticals. The contract provides for upfront…
Nutriband Receives Patent Notice of Publication for its Abuse Deterrent Transdermal Technology
Nutriband Inc. recently announced it has received a Notice of Publication of the Registration and Grant of a Standard Patent (R) from the Hong Kong…
Anocca Announces Submission of Clinical Trial Application for Multi-Asset Trial VIDAR-1 in Advanced Pancreatic Cancer
Anocca AB recently announced the submission of its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase 1/2 multi-asset umbrella…
Greenwich LifeSciences Partners With GIM in Italy
Greenwich LifeSciences, Inc. recently announced its partnership with clinical sites in Italy. The company has partnered with Gruppo Italiano Mammella (GIM), the largest academic cooperative…
